Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2′,3′-O-(N-methylanthraniloyl)-inosine 5′-triphosphate

Molecular Pharmacology

Volumn 80, Issue 1, 2011, Pages 87-96

  Hübner, Melanie ^a   Dixit, Anshuman ^b   Mou, Tung Chung ^c   Lushington, Gerald H ^b   Pinto, Cibele ^b   Gille, Andreas ^b   Geduhn, Jens ^a   König, Burkhard ^a   Sprang, Stephen R ^c   Seifert, Roland ^d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' O (N METHYLANTHRANILOYL)GUANOSINE TRIPHOSPHATE; 2',3' O (N METHYLANTHRANILOYL)INOSINE 5' TRIPHOSPHATE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; GUANOSINE TRIPHOSPHATE DERIVATIVE; INOSINE TRIPHOSPHATE; PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; STEREOCHEMISTRY;

ADENYLATE CYCLASE; ANIMALS; ENZYME INHIBITORS; INOSINE TRIPHOSPHATE; MAMMALS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959307998     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.071894     Document Type: Article

References (38)

1. Bashford D and Case DA (2000) Generalized Born models of macromolecular solvation effects. Annu Rev Phys Chem 51:129-152.
2. Bradbrook GM, Gleichmann T, Harrop SJ, Habash J, Raftery J, Kalb J, Yariv J, Hillier IH, and Helliwell JR (1998) X-ray and molecular dynamics studies of concanavalin-A glucoside and mannoside complexes relating structure to thermodynamics of binding. J Chem Soc Faraday Trans 94:1603-1611. (Pubitemid 128760331)
3. Chester JA and Watts VJ (2007) Adenylyl cyclase 5: a new clue in the search for the "fountain of youth"? Sci STKE 413:pe64.
4. Collaborative Computational Project Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
5. DeLano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA.
6. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. (Pubitemid 41742764)
7. Geduhn J, Dove S, Shen Y, Tang WJ, König B, and Seifert R (2011) Bis-halogenanthraniloyl- substituted nucleoside 5′-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin. J Pharmacol Exp Ther 336:104-115.
8. Gille A, Wenzel-Seifert K, Doughty MB, and Seifert R (2003) GDP affinity and order state of the catalytic site are critical for function of xanthine nucleotide-selective Gαs proteins. J Biol Chem 278:7822-7828. (Pubitemid 36800515)
9. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969. (Pubitemid 38623438)
10. Gille A, Guo J, Mou TC, Doughty MB, Lushington GH, and Seifert R (2005) Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5′-triphosphates, nucleoside 5′-[γ-thio]triphosphates and nucleoside 5′-[β,γ-imido]triphosphates. Biochem Pharmacol 71:89-97. (Pubitemid 41713530)
11. Gille A and Seifert R (2003) 2′(3′)-O-(N-methylanthraniloyl)- substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J Biol Chem 278:12672-12679. (Pubitemid 36800027)
12. Gille A and Seifert R (2004) Xanthine nucleotide-specific G-protein α-subunits: a novel approach for the analysis of G-protein-mediated signal transduction. Naunyn Schmiedebergs Arch Pharmacol 369:141-150. (Pubitemid 38292060)
13. Göttle M, Geduhn J, König B, Gille A, Höcherl K, and Seifert R (2009) Characterization of mouse heart adenylyl cyclase. J Pharmacol Exp Ther 329:1156-1165.
14. Gohlke H and Klebe G (2002) Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl 41:2644-2676.
15. Grobelny D, Goli UB, and Galardy RE (1989) Binding energetics of phosphoruscontaining inhibitors of thermolysin. Biochemistry 28:4948-4951. (Pubitemid 19162741)
16. Hiratsuka T (1983) New ribose-modified fluorescent analogs of adenine and guanine nucleotides available as substrates for various enzymes. Biochim Biophys Acta 742:496-508.
17. Hübner M, Dizayee S, Matthes J, Seifert R, and Herzig S (2011) Effect of MANTnucleotides on L-type calcium currents in murine cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol. doi:10.1007/s00210-011-0626-x.
18. Jameson DM and Eccleston JF (1997) Fluorescent nucleotide analogs: synthesis and applications. Methods Enzymol 278:363-390. (Pubitemid 27229929)
19. Kim KS, Lee KW, Baek IS, Lim CM, Krishnan V, Lee JK, Nestler EJ, and Han PL (2008) Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxietyrelated behavior. J Neurochem 107:105-115.
20. Laux WH, Pande P, Shoshani I, Gao J, Boudou-Vivet V, Gosselin G, and Johnson RA (2004) Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J Biol Chem 279:13317-13332. (Pubitemid 38468854)
21. Morgan BP, Scholtz JM, Ballinger MD, Zipkin ID, and Bartlett PA (1991) Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors. J Am Chem Soc 113:297-307.
22. Mou TC, Gille A, Fancy DA, Seifert R, and Sprang SR (2005) Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-triphosphate. J Biol Chem 280:7253-7261. (Pubitemid 40341283)
23. Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′,3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70:878-886. (Pubitemid 44268445)
24. Okumura S, Suzuki S, and Ishikawa Y (2009) New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene. J Pharmacol Sci 109:354-359.
25. Onufriev A, Bashford D, and Case DA (2000) A modification of the generalized Born model suitable for macromolecules. J Phys Chem B 104:3712-3720.
26. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. (Pubitemid 27085611)
27. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, and Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802. (Pubitemid 43078511)
28. Rottlaender D, Matthes J, Vatner SF, Seifert R, and Herzig S (2007) Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-[γ-thio] triphosphate. J Pharmacol Exp Ther 321:608-615. (Pubitemid 46624491)
29. s interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
30. Sunahara RK, Dessauer CW, and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480. (Pubitemid 26168706)
31. Suryanarayana S, Göttle M, Hübner M, Gille A, Mou TC, Sprang SR, Richter M, and Seifert R (2009) Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2′,3′-O-(2,4,6- trinitrophenyl)-substituted nucleoside 5′-triphosphates. J Pharmacol Exp Ther 330:687-695.
32. Taha HM, Schmidt J, Göttle M, Suryanarayana S, Shen Y, Tang WJ, Gille A, Geduhn J, König B, Dove S, et al. (2009) Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2′(3′)-O-(N-methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol 75:693-703.
33. Tang WJ and Hurley JH (1998) Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol Pharmacol 54:231-240.
34. sα. Methods Enzymol 345:198-206.
35. sα.GTPγS. Science 278:1907-1916.
36. Wang JL, Guo JX, Zhang QY, Wu JJ, Seifert R, and Lushington GH (2007) A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors. Bioorg Med Chem 15:2993-3002. (Pubitemid 46400467)
37. Wang JM, Wang W, and Kollman PA (2001) ANTECHAMBER: an accessory software package for molecular mechanical calculations. J Mol Graph 8:52-56.
38. Weiser J, Shenkin PS, and Still WC (1999) Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comp Chem 20:217-230. (Pubitemid 129653030)